FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely - to pulmonology. The invention contains two versions of implementing the method. Both versions involve introduction of dry powdered aerosol preparation tobramicine into the patient's endobronchial system. In the first version, one dose contains 90 to 130 mg of tobramicine or its pharmaceutically acceptable salt. At the first therapeutic stage, one dose is administered one to three times a day. Duration of the first therapeutic stage is 20 to 36 days. In the second version one dose contains 110 to 115 mg of tobramicine. At the first therapeutic stage, this therapeutic dose is administered twice a day. The first therapeutic stage lasts for 28 days. The therapeutic stage is followed by the second non-therapeutic stage. The non-therapeutic stage lasts for 26 to 30 days. At this stage no antibiotics are introduced into the patient's endobronchial system. Then the first and second therapeutic stages are performed again.
EFFECT: method provides required pharmacological effect by administering a smaller dose of dry powder tobramicine in a relatively short time in treating Pseudomonas infections in the patients suffering from cystic fibrosis.
24 cl, 11 tbl, 4 dwg
